Build a theory of ideal combination therapy strategies for overcoming late or acquired immunotherapy resistance in melanoma, based on the following results.
Build a theory of ideal combination therapy strategies for overcoming late/acquired immunotherapy resistance in melanoma, based on the following results.
Build a theory of the optimal duration of anti-PD-1 immunotherapy for melanoma, and whether it differs by depth of response, based on the following results.
Build a theory of the optimal duration of anti-PD1 immunotherapy for melanoma and whether it differs by degree of response, based on the following results.
Build a theory of the optimal duration of anti-PD1 immunotherapy for melanoma, and whether it differs by degree of response, based on the following results.
Build a theory of why giving neoadjuvant-adjuvant immunotherapy improves melanoma outcomes compared to adjuvant only immunotherapy, based on the following results.
Build a theory of why neoadjuvant-plus-adjuvant immunotherapy improves melanoma outcomes compared to adjuvant-only immunotherapy, based on the following results.
